vs
Liberty Broadband Corp（LBRDA）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是VERACYTE, INC.的1.9倍（$261.0M vs $139.1M），Liberty Broadband Corp净利率更高（146.7% vs 20.6%，领先126.1%），VERACYTE, INC.同比增速更快（21.5% vs 6.1%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 4.3%）
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
LBRDA vs VCYT — 直观对比
营收规模更大
LBRDA
是对方的1.9倍
$139.1M
营收增速更快
VCYT
高出15.4%
6.1%
净利率更高
LBRDA
高出126.1%
20.6%
两年增速更快
VCYT
近两年复合增速
4.3%
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.0M | $139.1M |
| 净利润 | $383.0M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | 15.7% | 16.3% |
| 净利率 | 146.7% | 20.6% |
| 营收同比 | 6.1% | 21.5% |
| 净利润同比 | 96.4% | — |
| 每股收益（稀释后） | $2.68 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LBRDAVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | — | $140.6M | ||
| Q3 25 | — | $131.9M | ||
| Q2 25 | $261.0M | $130.2M | ||
| Q1 25 | $266.0M | $114.5M | ||
| Q4 24 | $263.0M | $118.6M | ||
| Q3 24 | $262.0M | $115.9M | ||
| Q2 24 | $246.0M | $114.4M |
净利润LBRDAVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | $383.0M | $-980.0K | ||
| Q1 25 | $268.0M | $7.0M | ||
| Q4 24 | $291.0M | $5.1M | ||
| Q3 24 | $142.0M | $15.2M | ||
| Q2 24 | $195.0M | $5.7M |
毛利率LBRDAVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率LBRDAVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | — | 26.4% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | 15.7% | -4.0% | ||
| Q1 25 | 16.2% | 2.5% | ||
| Q4 24 | 4.9% | 3.5% | ||
| Q3 24 | 11.5% | 10.4% | ||
| Q2 24 | 8.5% | 4.0% |
净利率LBRDAVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | — | 29.3% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | 146.7% | -0.8% | ||
| Q1 25 | 100.8% | 6.2% | ||
| Q4 24 | 110.6% | 4.3% | ||
| Q3 24 | 54.2% | 13.1% | ||
| Q2 24 | 79.3% | 5.0% |
每股收益（稀释后）LBRDAVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | — | $0.50 | ||
| Q3 25 | — | $0.24 | ||
| Q2 25 | $2.68 | $-0.01 | ||
| Q1 25 | $1.87 | $0.09 | ||
| Q4 24 | $2.04 | $0.07 | ||
| Q3 24 | $0.99 | $0.19 | ||
| Q2 24 | $1.36 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $439.1M |
| 总债务越低越好 | $3.1B | — |
| 股东权益账面价值 | $10.4B | $1.3B |
| 总资产 | $16.6B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资LBRDAVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | $180.0M | $219.5M | ||
| Q1 25 | $226.0M | $186.1M | ||
| Q4 24 | $163.0M | $239.1M | ||
| Q3 24 | $168.0M | $274.1M | ||
| Q2 24 | $73.0M | $235.9M |
总债务LBRDAVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $3.8B | — | ||
| Q4 24 | $3.8B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | — |
股东权益LBRDAVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $10.4B | $1.2B | ||
| Q1 25 | $10.1B | $1.2B | ||
| Q4 24 | $9.8B | $1.2B | ||
| Q3 24 | $9.5B | $1.2B | ||
| Q2 24 | $9.3B | $1.1B |
总资产LBRDAVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $16.6B | $1.3B | ||
| Q1 25 | $17.0B | $1.3B | ||
| Q4 24 | $16.7B | $1.3B | ||
| Q3 24 | $16.3B | $1.3B | ||
| Q2 24 | $16.0B | $1.2B |
负债/权益比LBRDAVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.38× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.39× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $91.0M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | — |
| 自由现金流率自由现金流/营收 | 14.2% | — |
| 资本支出强度资本支出/营收 | 20.7% | — |
| 现金转化率经营现金流/净利润 | 0.24× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $-49.0M | — |
8季度趋势，按日历期对齐
经营现金流LBRDAVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | — | $52.6M | ||
| Q3 25 | — | $44.8M | ||
| Q2 25 | $91.0M | $33.6M | ||
| Q1 25 | $78.0M | $5.4M | ||
| Q4 24 | $1.0M | $24.5M | ||
| Q3 24 | $24.0M | $30.0M | ||
| Q2 24 | $27.0M | $29.6M |
自由现金流LBRDAVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | $37.0M | $32.3M | ||
| Q1 25 | $13.0M | $3.5M | ||
| Q4 24 | $-63.0M | $20.4M | ||
| Q3 24 | $-36.0M | $27.7M | ||
| Q2 24 | $-35.0M | $26.8M |
自由现金流率LBRDAVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | 34.7% | ||
| Q3 25 | — | 31.8% | ||
| Q2 25 | 14.2% | 24.8% | ||
| Q1 25 | 4.9% | 3.1% | ||
| Q4 24 | -24.0% | 17.2% | ||
| Q3 24 | -13.7% | 23.9% | ||
| Q2 24 | -14.2% | 23.4% |
资本支出强度LBRDAVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | 20.7% | 1.0% | ||
| Q1 25 | 24.4% | 1.6% | ||
| Q4 24 | 24.3% | 3.5% | ||
| Q3 24 | 22.9% | 1.9% | ||
| Q2 24 | 25.2% | 2.4% |
现金转化率LBRDAVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.29× | 0.76× | ||
| Q4 24 | 0.00× | 4.80× | ||
| Q3 24 | 0.17× | 1.98× | ||
| Q2 24 | 0.14× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LBRDA
暂无分部数据
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
